Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

In the latest trading session, Eli Lilly (LLY) closed at $804.99, marking a -0.39% move from the previous day.

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

Leerink notes Eli Lilly (LLY) terminated its volenrelaxin CKD due to failure of a “related heart failure study,” which has caused significant ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Tectonic Therapeutic (TECX) plunges as Eli Lilly (LLY) ends a mid-stage trial for its kidney drug volenrelaxin which is similar to TECX's lead drug TX45. Read more here.

Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $808.17 which represents a slight increase of $22.76 or 2.90% from the prior close of $785.41. The stock opened at $780.91 and ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.